This HTML5 document contains 67 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n19http://linked.opendata.cz/resource/drugbank/drug/DB00189/identifier/kegg-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/AHFS/
n13http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n8http://linked.opendata.cz/resource/drugbank/company/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00189/identifier/kegg-drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00189/identifier/drugbank/
n23http://bio2rdf.org/drugbank:
n17http://www.drugs.com/cons/
admshttp://www.w3.org/ns/adms#
n15http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00189/identifier/chebi/
n12http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB00189/identifier/pharmgkb/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00189/identifier/wikipedia/
n7http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00189
rdf:type
n3:Drug
n3:description
Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists. [Wikipedia]
n3:group
illicit withdrawn approved
n3:halfLife
Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours.
n3:indication
Used for short-term hypnotic therapy in the management of insomnia for periods of up to one week in duration; however, this medication generally has been replaced by other sedative-hypnotic agents.
n3:manufacturer
n8:271B5555-363D-11E5-9242-09173F13E4C5 n8:271B5554-363D-11E5-9242-09173F13E4C5
owl:sameAs
n15:DB00189 n23:DB00189
dcterms:title
Ethchlorvynol
adms:identifier
n10:Ethchlorvynol n11:PA164746383 n18:D00704 n19:C07833 n20:4882 n21:DB00189
n3:mechanismOfAction
Although the exact mechanism of action is unknown, ethchlorvynol appears to depress the central nervous system in a manner similar to that of barbiturates. Barbiturates bind at a distinct binding sites associated with a Cl<sup>-</sup> ionopore at the GABA<sub>A</sub> receptor, increasing the duration of time for which the Cl<sup>-</sup> ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
n3:synonym
1-Chloro-3-ethyl-pent-1-en-4-yn-3-ol ethyl β-chlorovinyl ethynyl carbinol 3-(beta-chlorovinyl)-1-pentyn-3-ol Placidyl 3-(β-chlorovinyl)-1-pentyn-3-ol 1-chloro-3-ethyl-1-penten-4-yn-3-ol β-chlorovinyl ethyl ethynyl carbinol
n3:toxicity
Symptoms of overdose include thrombocytopenia.
n5:hasAHFSCode
n6:28-24-92
n3:foodInteraction
Avoid alcohol Take with food to reduce irritation.
n3:proteinBinding
35-50%
n3:synthesisReference
Bayley, A. and McLamore, W.M.; U.S. Patent 2,746,900; May 22,1956; assigned to Chas. Pfizer & Co., Inc.
n12:hasConcept
n13:M0007824
foaf:page
n17:ethchlorvynol.html
n3:IUPAC-Name
n4:271B555A-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5560-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B555F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B555C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B555D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B555E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5558-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5571-363D-11E5-9242-09173F13E4C5 n4:271B5559-363D-11E5-9242-09173F13E4C5 n4:271B5556-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5557-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n7:N05CM08
n3:H-Bond-Acceptor-Count
n4:271B5566-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5567-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5561-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5562-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5564-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5563-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5565-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed from gastrointestinal tract.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
113-18-8
n3:category
n3:Bioavailability
n4:271B556C-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B5570-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B556E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B556F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B556B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B556A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B556D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B555B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5568-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5569-363D-11E5-9242-09173F13E4C5